Open AccessApremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial
Author(s) -
Gülen Hatemi,
Alfred Mahr,
Mitsuhiro Takeno,
Do Young Kim,
David Saadoun,
Haner Direşkeneli,
Melike Melikoğlu,
Sunfa Cheng,
Shan McCue,
Maria Paris,
Mindy Chen,
Yusuf Yazıcı
Publication year - 2021
Publication title -
clinical and experimental rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.184
H-Index - 95
eISSN - 1593-098X
pISSN - 0392-856X
DOI - 10.55563/clinexprheumatol/ra8ize
Subject(s) - apremilast , medicine , placebo , adverse effect , discontinuation , nausea , clinical endpoint , randomized controlled trial , disease , psoriatic arthritis , alternative medicine , pathology
This study assessed the efficacy and safety of apremilast for the oral ulcers associated with Behçet's syndrome (BS) up to 64 weeks.